ReSPECT™ Clinical Trials
  • RECURRENT GLIOBLASTOMA (GBM)
    • CANCER GUIDE FOR PATIENTS
      • DISEASE BACKGROUND
      • DIAGNOSIS
      • TREATMENT OPTIONS
      • RESOURCES
    • CLINCIAL TRIAL
      • TRIAL INFORMATION
        • QUICK OVERVIEW
      • TRIAL GUIDE FOR PATIENTS
      • PATIENT ELIGIBILITY
      • PRINCIPAL INVESTIGATORS
      • TRIAL LOCATIONS
      • NEXT STEPS
      • CONTACT US
      • NEWS
      • PUBLICATIONS
      • RESOURCES
  • LEPTOMENINGEAL METASTASES (LM)
    • CANCER GUIDE FOR PATIENTS
      • DISEASE BACKGROUND
      • DIAGNOSIS
      • TREATMENT OPTIONS
      • RESOURCES
    • CLINICAL TRIAL
      • TRIAL INFORMATION
      • PATIENT ELIGIBILITY
      • PRINCIPAL INVESTIGATORS
      • TRIAL LOCATIONS
      • CONTACT US
      • NEXT STEPS
      • NEWS
      • PUBLICATIONS
      • RESOURCES
  • PEDIATRIC BRAIN CANCER
    • CANCER GUIDE FOR PATIENTS- EPENDYMOMA
      • DISEASE BACKGROUND
      • DIAGNOSIS
      • TREATMENT OPTIONS
    • CANCER GUIDE FOR PATIENTS – HIGH GRADE GLIOMA
      • DISEASE BACKGROUND
      • DIAGNOSIS
      • TREATMENT OPTIONS
    • CLINICAL TRIAL
      • TRIAL INFORMATION
      • PRINCIPAL INVESTIGATORS
      • TRIAL LOCATIONS
      • NEXT STEPS
      • NEWS
      • PUBLICATIONS
      • RESOURCES
Select Page

NCCN Poster

by Plus Therapeutics | Apr 8, 2024 | LM

Our ReSPECT-LM Poster from the National Comprehensive Network (NCCN) Conference is now on our website at https://ir.plustherapeutics.com/presentations

Recent Posts

  • Plus Therapeutics: Advancing the Future of Radiotherapeutics in Cancer Care
  • FDA Clears IND for Plus Therapeutics’ REYOBIQ™ in Pediatric Brain Cancer Trial
  • Dr. Andrew Brenner Discusses Glioblastoma and REYOBIQ™ on KABB News
  • Spotlight on Dr. Toral Patel: Leading Brain Tumor Surgeon and Principal Investigator in the ReSPECT-GBM Clinical Trial
  • Honoring Brain Tumor Awareness Day: Supporting Glioblastoma Patients Through Advocacy and Innovation

Recent Comments

    • Expanded Access Policy
    • Privacy Policy
    • Terms of Use
    • Forward Looking Statement
    • Social Media Guidelines
    • ReSPECT Blog
    Copyright © 2025 Plus Therapeutics, Inc. All rights reserved. ReSPECT is a trademark of Plus Therapeutics, Inc. This website is intended for a U.S. audience only.
    This site uses cookies to improve your experience. A cookie is a file sent to your device when you access a site. By using this site, you agree to the use of cookies on your device for tracking and analytics. Cookie SettingsACCEPT
    Privacy & Cookies Policy

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
    Non-necessary
    Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
    SAVE & ACCEPT